Esophagitis as a complication of the combination of lenvatinib and pembrolizumab for advanced endometrial cancer: A case report

BACKGROUND: Pembrolizumab is a monoclonal antibody targeting the programmed cell death protein 1 (PD-1). It is used in the management and treatment of various oncologic conditions. To name a few: refractory and advanced melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell carcin...

Descripción completa

Detalles Bibliográficos
Autores principales: Fellouah, Massine, Auclair, Marie-Hélène, Fortin, Suzanne, Berdugo, Jérémie, de Guerké, Lara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Survey Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10457503/
https://www.ncbi.nlm.nih.gov/pubmed/37636497
http://dx.doi.org/10.1016/j.gore.2023.101235

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10457503/
https://www.ncbi.nlm.nih.gov/pubmed/37636497
http://dx.doi.org/10.1016/j.gore.2023.101235

Ejemplares similares